Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study aims to find best CMV prevention for kidney transplant patients

NCT ID NCT07430683

Disease control Sponsor: University of Guadalajara Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at two different approaches to prevent cytomegalovirus (CMV) infection in people who have received a kidney transplant from a living donor. The participants are at intermediate risk for CMV and are given standard anti-rejection medication. The goal is to see which strategy—daily preventive medication or monitoring and treating only if the virus appears—works better to keep patients healthy. Results may help doctors choose the best prevention plan for similar patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

68 people

The number who actually took part.

Started

Mar 2024

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. -Age ≥18 years. 2. -First living-donor kidney transplant. 3. -Intermediate CMV risk (recipient seropositive \[R+\], donor positive or negative \[D+/D-\]). 4-Induction immunosuppression with basiliximab. 5.-Ability to provide written informed consent. Exclusion Criteria: 1. -Multi-organ transplant recipients (e.g., pancreas-kidney, liver-kidney). 2. -Deceased donor transplant recipients. 3. -Primary non-function of the graft. 4. -Hyperacute rejection. 5. -Death within the first month post-transplant. 6. -Early graft loss due to surgical complications.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cytomegalovirus infections are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cytomegalovirus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cytomegalovirus infections

Contacts and locations

Locations

  • Universidad de Guadalajara

    Guadalajara, Jalisco, 44280, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.